Financial Counselors Inc. Has $530,000 Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Financial Counselors Inc. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 4.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,162 shares of the medical equipment provider’s stock after purchasing an additional 381 shares during the period. Financial Counselors Inc.’s holdings in Boston Scientific were worth $530,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BSX. Bruce G. Allen Investments LLC bought a new position in Boston Scientific during the fourth quarter valued at about $28,000. Venturi Wealth Management LLC increased its stake in Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 215 shares during the period. Coppell Advisory Solutions LLC bought a new position in Boston Scientific during the second quarter valued at about $34,000. Motco increased its stake in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares during the period. Finally, Sunbelt Securities Inc. bought a new position in Boston Scientific during the first quarter valued at about $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BSX shares. Needham & Company LLC boosted their price target on Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada upped their price objective on Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Oppenheimer upped their price objective on Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research note on Thursday, February 1st. BTIG Research reiterated a “buy” rating and issued a $64.00 price objective on shares of Boston Scientific in a research note on Friday, December 29th. Finally, Mizuho upgraded Boston Scientific from a “neutral” rating to a “buy” rating and upped their price objective for the company from $65.00 to $80.00 in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $68.14.

Insider Activity

In other news, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at approximately $3,509,213.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the sale, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. Insiders have sold a total of 50,979 shares of company stock valued at $3,418,529 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Down 1.1 %

NYSE:BSX opened at $68.07 on Friday. The stock’s fifty day moving average price is $66.99 and its two-hundred day moving average price is $59.37. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $69.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The company has a market cap of $99.87 billion, a price-to-earnings ratio of 63.62, a P/E/G ratio of 2.41 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the prior year, the business earned $0.45 EPS. On average, analysts anticipate that Boston Scientific Co. will post 2.25 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.